HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Inozyme Pharma (NASDAQ:INZY) and maintained a $14 price target.
July 02, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Inozyme Pharma and maintained a $14 price target.
The reiteration of a Buy rating and the maintenance of a $14 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100